GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women among the most common users.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.”

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

At a time when shedding pounds may be just a shot away, WeightWatchers is returning to its roots and its community to chart a new path forward.

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one demographic has been seen as increasingly important: cash-pay customers. These individuals,

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study suggests.